NCT04493619: A trial that was reported late by Opna Bio LLC
This trial has reported, although it was 264 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04493619 |
|---|---|
| Title | A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 11, 2020 |
| Completion date | April 25, 2022 |
| Required reporting date | April 25, 2023, midnight |
| Actual reporting date | Jan. 14, 2024 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 264 |